Phase 3 × NETWORK × Carcinoma, Ovarian Epithelial × Clear all Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
Phase 3 Completed
211 enrolled
Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase 3 Completed
819 enrolled
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
Phase 3 Withdrawn
Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer
Phase 3 Completed
571 enrolled 9 charts
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
Phase 3 Completed
61 enrolled
Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer
Phase 3 Completed
704 enrolled
S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Phase 3 Completed
308 enrolled
Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer
Phase 3 Completed
835 enrolled
Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
Phase 3 Completed
470 enrolled
Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
Phase 3 Completed
324 enrolled
Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer
Phase 3 Completed
384 enrolled
Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer
Phase 3 Terminated
Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients
Phase 3 Completed
115 enrolled
Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer
Phase 3 Terminated
38 enrolled